Get the Stockscreener App
162.92
3.49%
-5.90
Pre-market:
158.50
-4.42
-2.71%
Guardant Health Inc stock is traded at $162.92, with a volume of 2.47M.
It is down -3.49% in the last 24 hours and up +29.70% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$168.82
Open:
$168.03
24h Volume:
2.47M
Relative Volume:
0.94
Market Cap:
$21.60B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-47.91
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
+8.59%
1M Performance:
+29.70%
6M Performance:
+48.20%
1Y Performance:
+228.87%
1-Day Range:
$162.58
$169.27
1-Week Range:
$156.16
$174.08
52-Week Range:
$40.35
$174.08
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
162.92 | 21.60B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
516.62 | 191.99B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
194.19 | 137.44B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.25 | 44.98B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
281.27 | 40.28B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.14 | 37.04B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Responsive Playbooks and the GH Inflection - Stock Traders Daily
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
GH Maintained by Evercore ISI Group -- Price Target Raised to $2 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside - TradingView
Guardant Health stock hits 52-week high at $172.67 By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at $172.67 - Investing.com
Guardant Health: Great Execution, But At An Excessive Premium (NASDAQ:GH) - Seeking Alpha
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout | AI
Zydus and Apollo Hospitals sign MoU to launch MCD test in India - Yahoo Finance
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum - Investing.com
Guardant Health earnings on deck as cancer test volumes surge - Investing.com
Guardant Health stock surges on colon cancer blood test news - thestreet.com
GHGuardant Health Inc Latest SEC Filings - Finviz
Guardant Health (GH) Stock May Look Fully Valued Following Shield Coverage News - Yahoo Finance
Zydus, Guardant Health and Apollo Hospitals partner to launch multi-cancer blood test in India - Indian Pharma Post
Why Guardant Health (GH) Is Up 12.6% After Joining the Russell 1000 and Major Indexes – And What's Next - Yahoo Finance
Form 4 Guardant Health Inc For: 2 July By Investing.com - Investing.com Canada
Guardant Health (GH) CLO exercises RSUs as shares withheld for taxes - Stock Titan
Guardant Health (GH) CPO logs RSU vesting and $170.77 tax-withholding share transfer - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Kalia Kumud - Moomoo
Guardant Health (GH) CIO reports RSU vesting and tax share withholding - Stock Titan
Guardant Health (GH) CCO receives 7,414 shares from RSU vesting and tax withholding - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Chudova Darya - Moomoo
Guardant Health (GH) CTO vests RSUs; stock withheld to cover taxes - Stock Titan
Guardant Health (GH) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Bell Michael Brian - Moomoo
Guardant Health (GH) co-CEO exercises RSUs and pays taxes in stock - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Talasaz AmirAli - Moomoo
Guardant Health (GH) Co-CEO reports RSU vesting and tax share withholding - Stock Titan
Guardant Health (GH) director converts 155 RSUs into common shares - Stock Titan
Guardant Health (GH) Shares Surge Following UnitedHealth Coverage Announcement - GuruFocus
Guardant’s Shield colon cancer blood test snags UnitedHealth coverage - MedTech Dive
BTIG raises Guardant Health stock price target on insurance coverage By Investing.com - Investing.com South Africa
BTIG raises Guardant Health stock price target on insurance coverage - Investing.com
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $200 - Moomoo
Guardant Health rises following UnitedHealth coverage of Shield test - MSN
When Multi-Cancer Blood Screens Could Finally Take Off - Barron's
Guardant Health Stock Climbs As Analysts Hike Targets - timothysykes.com
Guardant Health (GH) files to resell 4,000 shares via cashless option exercise - Stock Titan
Guardant Health Stock Climbs As Wall Street Targets Surge - StocksToTrade
Guardant Health options trading jumps to 2,617 contracts By Investing.com - Investing.com Canada
Guardant Health (GH) Announces Coverage for Shield Colorectal Ca - GuruFocus
Guardant Health options trading jumps to 2,617 contracts - Investing.com
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening - Business Wire
Guardant Health Stock Climbs As FDA Win Fuels Bullish Targets - timothysykes.com
GH Maintained by BTIG -- Price Target Raised to $190 - GuruFocus
GH Stock At Over 5-Year Highs – What’s The UnitedHealth Connection? - Yahoo Finance
Guardant Health (GH) Shares Rise After UnitedHealth Coverage Ann - GuruFocus
Guardant Health (GH) Gains from United Healthcare Coverage Expan - GuruFocus
Guardant Health Stock Rises As FDA And Wall Street Back Growth Story - StocksToTrade
Guardant Health Stock Surges 19%, With A 5-Day Winning Spree - Trefis
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):